{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-055770","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.903238+00:00","generated_at":"2026-06-15T21:35:11.265743+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ironwood Q1 2023: net income $45.7M ($0.30 EPS); LINZESS demand up 10% YoY","bullets":["Total revenues $104.1M, up 7% YoY; GAAP net income $45.7M vs $38.8M.","LINZESS U.S. net sales $250M (+8% YoY); prescription demand grew 10% YoY.","Ended Q1 with $740M cash; full-year 2023 financial guidance maintained.","PDUFA date June 14 for potential pediatric functional constipation indication in ages 6-17."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-055770","json":"https://secwatch.observer/filing/0001104659-23-055770.json","markdown":"https://secwatch.observer/filing/0001104659-23-055770.md","text":"https://secwatch.observer/filing/0001104659-23-055770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923055770/0001104659-23-055770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923055770/tm2314422d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:35:11.265743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"36b5cf45150b0687497f8fbdb258a1aaaee76d8f","claim":"IRONWOOD PHARMACEUTICALS INC reported first quarter 2023 results: revenue $ 104,061, net income 45,714, EPS 0.30. Guidance reaffirmed.","evidence_excerpt":"supporting the next growth horizon for the company.” First Quarter 2023 Financial Highlights 1 (in thousands, except for per share amounts) 1Q 2023 1Q 2022 Total revenues $ 104,061 $ 97,529 Total operating expenses 43,964 39,683 GAAP net income 45,714 38,801 GAAP net income per share – basic 0.30 0.25 GAAP net income per share –diluted 0.25 0.21 Adjusted","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923055770/0001104659-23-055770-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Revenue","value":"$ 104,061"},{"label":"Net income","value":"45,714"},{"label":"EPS","value":"0.30"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}